Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344858 | 0.81 | GID4 (0.60) | GID4L3MBTL1PRCPDRD3GAA | |
| SCHEMBL2308014 | 0.78 | GID4 (0.53) | GID4L3MBTL1PRCPDRD3GAA | |
| SCHEMBL12761088 | 0.78 | GID4 (0.52) | GID4L3MBTL1PRCPDRD3GAA | |
| SCHEMBL2359018 | 0.76 | GID4 (0.71) | GID4L3MBTL1PRCPDRD3GAA | |
| SCHEMBL20912489 | 0.76 | GID4 (0.71) | GID4L3MBTL1PRCPDRD3GAA | |
| SCHEMBL20912502 | 0.76 | GID4 (0.71) | GID4L3MBTL1PRCPDRD3GAA | |
| SCHEMBL12761049 | 0.72 | GID4 (0.60) | GID4L3MBTL1PRCPDRD3TAAR1 | |
| SCHEMBL8492295 | 0.71 | GID4 (0.55) | GID4L3MBTL1DRD3TAAR1KMT2A | |
| SCHEMBL12760970 | 0.70 | GID4 (0.62) | GID4L3MBTL1DRD3GAATAAR1 | |
| SCHEMBL4344185 | 0.70 | GID4 (1.00) | GID4L3MBTL1PRCPDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2350093-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2010046108-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | KCNQ1, KCNQ3, KCNQ2 | GID4 2166/4885L3MBTL1 2790/4885PRCP 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.